Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.

By J. Gelfand, R. Weinstein, S. Porter, A. Neimann, Jesse Berlin, D. Margolis. Archives of Dermatology, 2005

654 citations recorded by the source corpus.

Subfields: Immunology, Infectious Diseases, Rheumatology

View Paper: https://www.semanticscholar.org/paper/5e2cbd5bd794965be9a947fc39b1022a76173754

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Andrea B. Troxel
2. J. Gelfand
3. M. Lebwohl

In Rheumatology

1. Andrea B. Troxel
2. J. Gelfand

Citations in the corpus

• The risk of depression, anxiety and suicidality in patients with psoriasis: A population-based cohort study (2010, methodology): “This method for classification of psoriasis has been previously validated and used in several peer-reviewed publications.(2-4,21,22)”
• Global epidemiology of psoriasis: a systematic review of incidence and prevalence. (2013, background): “…the United Kingdom, Germany, Russia, and United States there was an increasing trend with age until around 60 years, after which the prevalence reduced (Osmanova, 1985; Javitz et al., 2002; Stern et al., 2004; Gelfand et al., 2005b; Schlander et al., 2008; Seminara et al., 2011; Tsai et al., 2011).”
• Is folic acid good for everyone? (2008, background): “5% prevalence, 900 000 (43) Folic acid may modify response”
• Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. (2010, background): “1,9,17,18 In addition, the increased risk of CV death and point estimates were robust to a variety of sensitivity analyses ( Table 5 ).”
• Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008, background): “Approximately 80% of those affected with psoriasis have mild to moderate disease, with 20% having moderate to severe psoriasis affecting more than 5% of the body surface area (BSA) or affecting crucial body areas such as the hands, feet, face, or genitals.(5,6)”